Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates. Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates Post navigation Previous: Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare ConferenceNext: Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
